Maia Biotechnology, Inc. · AMEX:MAIA
Maia Biotechnology — Investor Presentation (June 2024)
32 slides from Maia Biotechnology's investor presentation, Jun 4, 2024
Slide 1: Telomere Targeting Immunotherapies for Cancer
Exhibit 99.1 TELOMERE TARGETING IMMUNOTHERAPIES FOR CANCER NYSE AMERICAN: MAIA June 2024
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS NYSE American: MAIA All statements in this presentation, other than those relating to historical facts, are forward-looking statements. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans, and strategies; state
Slide 3: Investment Profile
INVESTMENT PROFILE NYSE American: MAIA New science for cancer therapy: dual MOA telomere targeting and immunogenicity. • Lead molecule THIO in clinic; 2nd generation compounds in R&D Phase 2 trial THIO-101 nearing completion: THIO sequenced with CPI in NSCLC. • Unprecedented disease control, respons
Slide 4: Robust Pipeline
ROBUST PIPELINE NYSE American: MAIA PHASE 1 PHASE 2 PHASE 3 COLLABORATION & RIGHTS THIO Telomere targeting agent Patient Enrollment Worldwide rights (THIO → Libtayo®) THIO-101 NSCLC-2+ Complete owned by MAIA Ph 2 Worldwide rights (THIO → CPI) CRC, HCC, SCLC, ST THIO-102 Planning owned by MAIA Ph 2/3
Slide 5: Mission and Approach
NYSE American: MAIA MISSION AND APPROACH 5 5
Slide 6: Cancer is the most dominant age-related disease
NYSE American: MAIA Population aged >80 expected to triple by 2050 Cancer is the 142 At age 90: most dominant million 40% will be diagnosed age-related 20% will die of it 426 disease 2020 million Cancer is the most dominant of the age-related disease categories and has life altering impacts in the l
Slide 7: THIO is the only direct telomere targeting anticancer agent in clinical development
NYSE American: MAIA THIO is the only direct telomere targeting anticancer agent in clinical development 77
Slide 8: THIO – Novel Mechanisms of Action
CCCCA A THIO – NOVEL MECHANISMS OF ACTION NYSE American: MAIA Immune Checkpoint Inhibitor THIO THIO has a dual MoA: 1 • Telomere targeting (durvalumab) (cemiplimab) • Immunogenic effect 2 (pembrolizumab) (tislelizumab) Followed by (atezolizumab) THIO (nivolumab) Chromosome Telomere Partnership with
Slide 9: THIO-101 NSCLC Trials - Rationale
THIO-101 NSCLC TRIALS - RATIONALE NYSE American: MAIA Cycle 1 Cycle 2 • THIO followed by CPI results in 60% 1000 Control complete response 900 Atezolizumab • Only 2 cycles of therapy were 800 THIO administered on weeks 1 and 2; no No cancer THIO → Atezo 700 further therapy throughout the study immun
Slide 10: THIO-101 Trial Non-Small Cell Lung Cancer
NYSE American: MAIA THIO-101 TRIAL NON-SMALL CELL LUNG CANCER 10 10
Slide 11: Regeneron Agreement &
REGENERON AGREEMENT NYSE American: MAIA & 11
Slide 12: THIO-101 - Trial Design
THIO-101 - TRIAL DESIGN NYSE American: MAIA A Multicenter, Open-Label, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with LIBTAYO® (cemiplimab) in NSCLC patients RESISTANT TO CHECKPOINT INHIBITORS Part A: Part B: Expansion: 1 Safety Efficacy / Safety
Slide 13: Patients' Survival by Line of Therapy
PATIENTS' SURVIVAL BY LINE OF THERAPY NYSE American: MAIA Second Line (All Doses): 45 patients Third Line+ (All Doses): 24 patients 13.5 months 14.6 months 12.8 months 12.8 months 12.5 months Legend Treatment Follow-Up Median Survival Stable Disease (SD) Follow-Up (3L+) Partial Response (PR) 8.9 mon
Slide 14: Treatment in Third-Line
TREATMENT IN THIRD-LINE Third Line (All Doses): 20 patients Extended Survival • 20 subjects in 3L completed at least 1 post baseline assessment at time of cut-off • 13/20 (65%) patients crossed 5.8 months OS threshold • 17/20 (85%) crossed 2.5 months PFS threshold Unprecedented Efficacy • DCR 85% vs
Slide 15: Best 3L Results in the 180mg Dose
BEST 3L RESULTS IN THE 180MG DOSE Third Line (180mg): 8 patients NSCLC-3 – 180mg: • 6/8 (75%) patients crossed 5.8 months OS threshold • 7/8 (88%) crossed 2.5 months PFS threshold Legend Treatment Follow-Up Stable Disease (SD) Partial Response (PR) Median Survival Progressive Disease (PD) Follow-Up
Slide 16: Expected Efficacy vs. Current Treatments
EXPECTED EFFICACY VS. CURRENT TREATMENTS NYSE American: MAIA Third-Line THIO (180mg) + Tarceva® Taxotere® Chemotherapy NSCLC Libtayo® (cemiplimab) (erlotinib) (docetaxel) Population CPI Resistant (3L) CPI Naïve (3L) CPI Naïve (2L+) CPI Naïve (2L) DCR 88% 36% 45% 54% ORR 38% 6% 9% 5.7% 1.9 months 5.5
Slide 17: Planned Upcoming Trials
NYSE American: MAIA PLANNED UPCOMING TRIALS 17 17
Slide 18: THIO-102 Trial (Planned)
THIO-102 TRIAL (PLANNED) NYSE American: MAIA A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Anti-PD-1 or Anti-PD-L1 Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 2 Baskets Umbrella Arms Colorectal Cancer (CRC) TECENTRIQ (ate
Slide 19: THIO-102 – Colorectal Rationale
THIO-102 – COLORECTAL RATIONALE NYSE American: MAIA 700 Control • THIO followed by CPI results in 100% 600 Atezolizumab complete response 500 THIO • Only 2 cycles of therapy were 400 THIO → Atezo administered on weeks 1 and 2; no 300 further therapy throughout the study 200 100% CR • No recurrence a
Slide 20: SCLC & HCC – Orphan Drug Designation
SCLC & HCC – ORPHAN DRUG DESIGNATION NYSE American: MAIA HCC SCLC 1500 1500 Control Control 1250 1250 THIO Pembro → THIO 1000 1000 THIO → IR THIO → Pembro 750 750 IR + Atezo THIO → IR + Atezo 500 500 250 250 0 0 0 5 10 15 20 25 0 5 10 15 20 25 Days After Tumor Inoculation Days After Tumor Inoculatio
Slide 21: Excellent Efficacy in HCC Models
EXCELLENT EFFICACY IN HCC MODELS NYSE American: MAIA HCC • THIO achieved complete and durable responses in Hepatocellular Carcinoma (HCC), the dominant histology in primary liver cancer (90%), in in vivo models 100% CR 21
Slide 22: HCC Anti-Cancer Immune Memory
HCC ANTI-CANCER IMMUNE MEMORY NYSE American: MAIA HCC • When combined with immunotherapy checkpoint inhibitor Libtayo®, duration of response was further potentiated • Upon rechallenge with two times more cancer cells and no additional treatment, tumor growth was completely prevented HCC Rechallenge
Slide 23: THIO-103 Trial (Planned)
THIO-103 TRIAL (PLANNED) NYSE American: MAIA A Multicenter, Open-label, Phase 2 Trial Evaluating the Safety and Efficacy of THIO Administered in Sequence with Anti-PD-1 or Anti-PD-L1 Part A/B: Safety/Efficacy Signal Part C: Pivotal Phase 3 Baskets 1 SCLC First Line EP + TECENTRIQ (atezolizumab) THIO
Slide 24: Investment Opportunity
NYSE American: MAIA INVESTMENT OPPORTUNITY 24 24
Slide 25: Exclusivity and Intellectual Property
EXCLUSIVITY AND INTELLECTUAL PROPERTY NYSE American: MAIA Goal: New Chemical Entity (NCE) Marketing Exclusivity • THIO has never been previously approved by the FDA for commercialization • Robust exclusivity • US: 7 years; EU, Japan, other markets: 10 years Robust and Growing Patent Portfolio for TH
Slide 26: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM NYSE American: MAIA Vlad Vitoc, MD, MBA Sergei Gryaznov, PhD Jeffrey Himmelreich, MBA Founder and CEO Chief Scientific Officer Head of Finance • 24+ years in Oncology Pharma/ • 25+ years as Scientist • 20+ years of financial Biotech: Commercial, Medical • Expert Drug Disc
Slide 27: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY NYSE American: MAIA Developing agents for the top tumor Checkpoint Inhibitors Market types markets globally 2023 Sales ($B) NSCLC (#1 WW) HCC 30 Mortality: 1.7M / Sales: $34B Mortality: 0.8M / Sales: $3B 25 25 CRC (#2 WW) SCLC 20 Mortality: 1.0M / Sales: $20B Mortality
Slide 28: Comparable Companies
COMPARABLE COMPANIES NYSE American: MAIA $2.5B $95M $4.1B $0.8B $1.5B $4.1B Market Cap Market Cap Market Cap Market Cap Market Cap Market Cap $4.36/share $58/share $12/share $9/share $21/share $76/share • On June 3, 2022, Bristol Myers Squibb (BMS) announced the acquisition of Turning Point Therapeu
Slide 29: Multiple Value-Driving Milestones
MULTIPLE VALUE-DRIVING MILESTONES NYSE American: MAIA • Major inflection points 2024 2025 2026 Part B Part B Part B Part C Part C Filing for Potential Early THIO-101 Efficacy Long-term Full Efficacy Enrollment US Accelerated Efficacy Ph2 (ASCO) Complete approval Update Efficacy Efficacy Update Appro
Slide 30: Thank You
NYSE American: MAIA THANK YOU Investor Relations Contact +1 (872) 270-3518 ir@maiabiotech.com MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 Chicago, IL 60606 30 30
Slide 31: Appendix
NYSE American: MAIA APPENDIX 31 31
Slide 32: U.S. FDA Granted Orphan Drug Designations to THIO
U.S. FDA GRANTED 3 ORPHAN DRUG DESIGNATIONS TO THIO NYSE American: MAIA • The FDA’s Orphan Drug Act of 1983 is designed to incentivize the development of therapies that demonstrate promise for the 3x treatment of rare (orphan) diseases or conditions • Rare disease - affects fewer than 200,000 people
MAIA Biotechnology — Investor Presentation (June 2024) on 6ix